CA2239732A1 - Methode de traitement de la douleur - Google Patents

Methode de traitement de la douleur Download PDF

Info

Publication number
CA2239732A1
CA2239732A1 CA002239732A CA2239732A CA2239732A1 CA 2239732 A1 CA2239732 A1 CA 2239732A1 CA 002239732 A CA002239732 A CA 002239732A CA 2239732 A CA2239732 A CA 2239732A CA 2239732 A1 CA2239732 A1 CA 2239732A1
Authority
CA
Canada
Prior art keywords
thiadiazol
tetrahydro
methylpyridine
branched
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002239732A
Other languages
English (en)
Inventor
Charles Howard Mitch
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2239732A1 publication Critical patent/CA2239732A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processing Of Meat And Fish (AREA)

Abstract

Méthode et composition de traitement de la douleur au moyen d'une composition comprenant un composé azabicyclique ou tétrahydropyridine et un composé analgésique classique.
CA002239732A 1995-12-07 1996-12-05 Methode de traitement de la douleur Abandoned CA2239732A1 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US831895P 1995-12-07 1995-12-07
US831295P 1995-12-07 1995-12-07
US831395P 1995-12-07 1995-12-07
US829595P 1995-12-07 1995-12-07
US830695P 1995-12-07 1995-12-07
US831995P 1995-12-07 1995-12-07
US829895P 1995-12-07 1995-12-07
US60/008,298 1995-12-07
US60/008,318 1995-12-07
US60/008,312 1995-12-07
US60/008,313 1995-12-07
US60/008,319 1995-12-07
US60/008,306 1995-12-07
US60/008,295 1995-12-07
PCT/US1996/019390 WO1997020556A1 (fr) 1995-12-07 1996-12-05 Methode de traitement de la douleur

Publications (1)

Publication Number Publication Date
CA2239732A1 true CA2239732A1 (fr) 1997-06-12

Family

ID=27567403

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002239732A Abandoned CA2239732A1 (fr) 1995-12-07 1996-12-05 Methode de traitement de la douleur

Country Status (14)

Country Link
EP (1) EP0866702A4 (fr)
JP (1) JP2000501711A (fr)
KR (1) KR19990071977A (fr)
CN (1) CN1208348A (fr)
AU (1) AU715645B2 (fr)
CA (1) CA2239732A1 (fr)
CZ (1) CZ174598A3 (fr)
EA (1) EA199800535A1 (fr)
HU (1) HUP0000110A3 (fr)
IL (1) IL124786A0 (fr)
NO (1) NO982582L (fr)
NZ (1) NZ324594A (fr)
PL (1) PL327144A1 (fr)
WO (1) WO1997020556A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE248166T1 (de) 1999-06-04 2003-09-15 Lilly Co Eli 7-oxo-2-azabicyclo(2.2.1)heptane als selektive muskarin-rezeptor antagonisten
CA3042642A1 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP2022523355A (ja) * 2019-02-22 2022-04-22 カルナ セラピューティックス，インコーポレイテッド 神経障害の処置のための重水素化キサノメリンの化合物及び方法
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863B (zh) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5527813A (en) * 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
WO1993014089A1 (fr) * 1992-01-13 1993-07-22 Novo Nordisk A/S Composes heterocycliques, leur preparation et leur utilisation
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation

Also Published As

Publication number Publication date
CZ174598A3 (cs) 1999-01-13
CN1208348A (zh) 1999-02-17
HUP0000110A2 (hu) 2000-06-28
EP0866702A1 (fr) 1998-09-30
EP0866702A4 (fr) 2001-07-25
PL327144A1 (en) 1998-11-23
NO982582D0 (no) 1998-06-05
NO982582L (no) 1998-08-03
KR19990071977A (ko) 1999-09-27
IL124786A0 (en) 1999-01-26
AU715645B2 (en) 2000-02-10
WO1997020556A1 (fr) 1997-06-12
EA199800535A1 (ru) 1998-12-24
HUP0000110A3 (en) 2000-09-28
AU1147697A (en) 1997-06-27
JP2000501711A (ja) 2000-02-15
NZ324594A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
JP4571236B2 (ja) ミューオピオイド作用薬およびカッパ−２オピオイド作用薬のサブ鎮痛用量共同投与による鎮痛性相乗作用を惹起する鎮痛組成物およびその製造方法
US6995169B2 (en) Analgesic compositions containing buprenorphine
HU206042B (en) Process for producing pharmaceutical compositions comprising indole-3-carboxylic acid-endo-8-methyl-8-azabicyclo/3.2.1./oct-3-yl ester and/or 1,2,3-9-tetrahydro-9-methyl-3-(2-methyl-1h-imidazol-1-yl)-methyl-4h-carbazol-4-one, with an activity preventing or reducing opiate-, alcohol- and nicotine-dependence
CA2250042A1 (fr) Traitement de la douleur par l'utilisation d'une combinaison synergique d'un antipsychotique atypique et un medicament utilise dans le traitement de la douleur
US5057519A (en) 5-HT3 antagonists: use in reducing opiate tolerance
US20060240085A1 (en) Treatment of dependence withdrawal
CA2239732A1 (fr) Methode de traitement de la douleur
Stewart et al. The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat
WO1997020556A9 (fr) Methode de traitement de la douleur
AU705031B2 (en) Composition for treating pain
Swedberg et al. Butylthio [2.2. 2](NNC 11–1053/LY297802): an orally active muscarinic agonist analgesic
EP1007041A1 (fr) Composition analgesique
RU2419433C2 (ru) Средство для профилактики или лечения алкогольной зависимости и зависимости от лекарственных веществ
WO1998046601A1 (fr) Composition pour le traitement de la douleur
US6511982B2 (en) Treatment of pain
AU716972B2 (en) Method for treating bipolar disorder
EP0709093A2 (fr) Utilisation d'une oxadiazole ou thiadiazole azabicyclique dans le traitement de l'anxiété
MXPA98004525A (en) Method for treating do
US6635237B2 (en) Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence
MXPA98004519A (en) Composition to treat do
Jasinski Clinical aspects of opiate antagonists and partial agonists
RIPAMΟΝΤΙ 8 Pharmacology of opioid analgesia: clinical principles
JPWO2001022997A1 (ja) 鎮痛薬

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued